Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care?
0/5 보강
APA
Lee JJ, Desai CS, Kim HJ (2026). Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care?. Gland surgery, 15(1), 3. https://doi.org/10.21037/gs-2025-aw-498
MLA
Lee JJ, et al.. "Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care?." Gland surgery, vol. 15, no. 1, 2026, pp. 3.
PMID
41668911
같은 제1저자의 인용 많은 논문 (5)
- DNA-PKcs orchestrates CTLA-4 depletion-induced senescence in cancer cells.
- Practical and versatile hypochlorite sensor using a xanthene scaffold: Integrating theoretical analysis with environmental and biological applications.
- Usefulness of Charlson comorbidity index-adjusted mortality prediction tools and factors influencing mortality in intensive care unit patients: a retrospective medical record review-based study.
- Spatially-guided metabolomics profiling of metabolic regions in human tumor tissues.
- A TIMELESS link to dedifferentiation in thyroid cancer.